iShares Biotechnology ETF (IBB)
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
Cetera Investment Advisers Buys 10,994 Shares of iShares Biotechnology ETF $IBB
Cetera Investment Advisers raised its stake in shares of iShares Biotechnology ETF (NASDAQ: IBB) by 9.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 128,530 shares of the financial services provider's stock after purchasing an additional 10,994 shares
Healthcare Systems' Liquidity Challenge
Healthcare systems are facing rising operating pressure, thinner margins, and a harder question about how to manage liquidity across the balance sheet as capital needs become more uncertain. Liquidity is an issue, and an enterprise risk management approach that factors in organizational risks when setting investment strategy can help.
3 Healthcare ETFs to Own in a Choppy Stock Market
Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.
SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.44% for iShares Biotechnology ETF. iShares' ETF provides concentrated exposure to 248 biotechnology stocks while the SPDR fund holds 59 diverse healthcare names.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.
Biotech's Silent Resurgence (5-Year Base Breakout)
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
Should You Invest in the iShares Biotechnology ETF (IBB)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on February 5, 2001.
IBB: Space Stocks And AI Stealing The Risk-On Show In 2026
I reiterate a Hold rating on the iShares Nasdaq Biotechnology ETF, citing modest valuation but lackluster momentum and unfavorable market themes. IBB lags the S&P 500 YTD and faces headwinds as speculative capital favors AI and space stocks over biotech. The ETF's technical setup is mixed, with key resistance at $170 and potential upside to $190 if a breakout occurs.
AV Laboratories, Founded by Pioneers of IVF Solutions, to Launch Fertility Clinic Program Featuring Its Award-Winning Skincare at ESHRE 2026 in London
LONDON--(BUSINESS WIRE)---- $IBB #AVLSOM3--AV Laboratories, a science-led skincare company founded by pioneers in IVF solutions, regenerative medicine, and stem cell therapy, today announced it will exhibit at the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE 2026, taking place in London from 5 - 8 July 2026. The company will welcome clinicians, embryologists, fertility specialists, researchers, partners, and industry participants at Booth A22. “ESHRE is deeply personal.
Biotech Investors Are Tuning Out the MAHA Chaos
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
Locking In A Quick Gain In This Biotech ETF Made Room For Better Swing Trades; Here's Why
Locking in profits while you have them can help avoid downturns.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now
Biotech has reasserted itself over the past year as drug approvals,
Should You Invest in the iShares Biotechnology ETF (IBB)?
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on February 5, 2001.
iShares Biotechnology ETF $IBB Shares Bought by Assetmark Inc.
Assetmark Inc. grew its holdings in shares of iShares Biotechnology ETF (NASDAQ: IBB) by 150,979.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,029 shares of the financial services provider's stock after purchasing an additional 73,980 shares during
Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead
The bulk of coverage towards the top gaining stock sectors over the past year has focused understandably on technology, which has made huge strides, with semiconductors exceeding +60%.
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
DAFNA Capital Management LLC sold 34,405 shares of iShares Biotechnology ETF (IBB) Quarter-end position value decreased by $3.31 million, reflecting both trading and stock price effects Trade represented a 1.3% reduction of 13F reportable assets under management Post-trade holding: 68,095 shares valued at $11.49 million IBB accounted for 2.67% of fund AUM after the trade, placing it outside the fund's top five holdings
Bank of America Corp DE Lowers Holdings in iShares Biotechnology ETF $IBB
Bank of America Corp DE lowered its position in iShares Biotechnology ETF (NASDAQ: IBB) by 4.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,893,841 shares of the financial services provider's stock after selling 243,108 shares during the
Aster Capital Management DIFC Ltd Makes New Investment in iShares Biotechnology ETF $IBB
Aster Capital Management DIFC Ltd bought a new position in iShares Biotechnology ETF (NASDAQ: IBB) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 13,210 shares of the financial services provider's stock, valued at approximately $1,907,000. iShares Biotechnology ETF comprises about 1.0%